Home
Storia in 1 fonti
Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
Raccontata da
morningstar.com
Timeline cronologica
- ·
Pentixapharm Holding AG: FDA grants "Study May Proceed" for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10…
Pentixapharm Holding AG: FDA grants "Study May Proceed" for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting…
- ·
Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
- ·
[68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market
[68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market